All In Biotech

Drug Trial Radar · NCT02852967

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

A Phase 2 Study, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy, Tolerability, and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy

Last checked: Nov 20, 2026Latest source record: Mar 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

110

Actual

Start

Sep 14, 2016

Primary completion

Feb 13, 2019

Study completion Feb 13, 2019

Sponsor

Lead sponsor
Kadmon Corporation, LLCSanofi (SNY)
Sponsor type
Industry
First posted
Aug 2, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, randomized, placebo-controlled, 2-period study to evaluate the safety, tolerability, and efficacy of belumosudil in adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Conditions

  • Chronic Plaque Psoriasis

Interventions

  • BelumosudilDrug

  • PlaceboDrug

    Placebo tablets matching belumosudil

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and ObservedTime frame: 16 weeks

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Alliance Dermatology and Mohs Center

    Phoenix, Arizona

  • University of California, Irvine - Dermatology Clinical Research Center

    Irvine, California

  • Dermatology Research Associates

    Los Angeles, California

  • Renstar Medical Research

    Ocala, Florida

  • Dawes Fretzin Dermatology Group

    Indianapolis, Indiana

  • Dermatology Specialists Research

    New Albany, Indiana

  • Dermatology Specialists Research

    Louisville, Kentucky

  • Metro Boston Clinical Partners

    Brighton, Massachusetts

  • Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey

  • Sadick Research Group

    New York, New York

  • Oregon Dermatology and Research Center

    Portland, Oregon

  • Tennessee Clinical Research Center

    Nashville, Tennessee

  • Suzanne Bruce and Associates

    Katy, Texas

  • Austin Institute for Clinical Research

    Pflugerville, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.